Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder

Daniel J. Liput, Dana C. Hammell, Audra L. Stinchcomb, Kimberly Nixon

Abstract

Excessive alcohol consumption, characteristic of alcohol use disorders, results in neurodegeneration and behavioral and cognitive impairments that are hypothesized to contribute to the chronic and relapsing nature of alcoholism. Therefore, the current study aimed to advance the preclinical development of transdermal delivery of cannabidiol (CBD) for the treatment of alcohol-induced neurodegeneration. In Experiment 1, 1.0%, 2.5% and 5.0% CBD gels were evaluated for neuroprotection. The 5.0% CBD gel resulted in a 48.8% reduction in neurodegeneration in the entorhinal cortex assessed by Fluoro-Jade B (FJB), which trended to statistical significance (p = 0.069). Treatment with the 5.0% CBD gel resulted in day 3 CBD plasma concentrations of ~100.0 ng/mL so this level was used as a target concentration for development of an optimized gel formulation. Experiment 2 tested a next generation 2.5% CBD gel formulation, which was compared to CBD administration by intraperitoneal injection (IP; 40.0 mg/kg/day). This experiment found similar magnitudes of neuroprotection following both routes of administration; transdermal CBD decreased FJB+ cells in the entorhinal cortex by 56.1% (p < 0.05), while IP CBD resulted in a 50.6% (p < 0.05) reduction in FJB+ cells. These results demonstrate the feasibility of using CBD transdermal delivery systems for the treatment of alcohol-induced neurodegeneration.

1. Introduction

Approximately 8.5% of the U.S. population currently meets the diagnostic criteria for an alcohol use disorder (AUD; Hasin et al., 2007). Although four pharmacotherapy based interventions are approved in the U.S. for the treatment of AUDs, these drugs have had limited efficacy in the patient population (Litten et al., 2012). Additionally, these medications primarily target the motivational properties of alcohol, while the neurodegenerative effects of alcohol that are hypothesized to impair behavioral control and decision making, are not managed by these specific treatments. Therefore, identification of novel targets and development of new therapeutic agents is critical to improve pharmacotherapy based treatment strategies for AUDs.

Neuroprotective agents are hypothesized to have high therapeutic utility for the treatment of AUDs (Crews, 1999). Excessive alcohol intake, characteristic of AUDs, results in neurodegeneration and cognitive and behavioral impairment, effects which are hypothesized to influence the transition to addiction (Koob and Le Moal, 1997; Crews, 1999; Sullivan and Pfefferbaum, 2005). Imaging studies have identified gross anatomical abnormalities throughout the brains of human alcoholics including widespread disruption of white matter tracts, atrophied cortical gray matter and increased cerebral spinal fluid filled space (Pfefferbaum et al., 1992; Mechtcheriakov et al., 2007; Demirakca et al., 2011). These effects have also been observed in post-mortem studies showing significant cortical neuronal loss in alcoholic brains (Harper and Kril, 1989; Kril et al., 1997), which is consistent with studies demonstrating long term or permanent deficits in function (Stavro et al., 2012). Some brain structures appear to be more susceptible to the neurodegenerative effects of alcohol, including the frontal lobe (Kril et al., 1997; Pfefferbaum et al., 1997; Qin and Crews, 2012), temporal lobe (Sullivan et al., 1995) and hippocampus (Sullivan et al., 1995). The aforementioned brain regions are involved in problem solving, attention, information processing, learning and memory and behavioral control, therefore it is not surprising that these functions are impaired in AUDs (Stavro et al., 2012). Importantly, a recent study described an association between reductions in cortical gray matter and risk for relapse (Rando et al., 2011), further substantiating the role of alcohol-induced neurodegeneration in AUDs. Therefore, elucidating the mechanism(s) underlying alcohol-induced neurodegeneration and developing neuroprotective pharmacotherapies could improve prevention and treatment strategies for AUDs.

Studies have suggested that chronic alcohol exposure is associated with induction of neuroinflammatory mediators and/or oxidative stress, including inflammatory mediators and oxidative stress, which can lead to neuronal cell death. Cannabidiol (CBD) is a major constituent of cannabis, a plant that has been used for medicinal purposes for thousands of years. CBD has been shown to have anti-inflammatory and anti-oxidative properties as well as neuroprotective effects. In animal models of alcohol-induced neurodegeneration, CBD has been shown to reduce neuronal loss and improve behavioral outcomes. Therefore, the current study aimed to advance the preclinical development of transdermal delivery of CBD for the treatment of alcohol-induced neurodegeneration.
which leads to neurodegeneration (Crews and Nixon, 2009; Qin and Crews, 2012). Consistent with this hypothesis, a variety of antioxidants, including α-tocopherol, butylated hydroxytoluene (BHT) and cannabidiol (CBD) have been effective in reducing binge alcohol-induced neurodegeneration (Hamelink et al., 2005; Crews et al., 2006). Neuroprotection mediated by antioxidant treatment is associated with inhibition of NF-κB–DNA binding, reductions of COX-2 expression and microglial activation (Crews et al., 2006), all of which support the hypothesis that neuroinflammatory signaling and/or oxidative stress contribute to alcohol-induced neurodegeneration (Crews and Nixon, 2009). These studies have clearly demonstrated that antioxidants protect against alcohol-induced neurodegeneration, therefore further development of these agents for clinical use is warranted.

CBD is a main constituent of Cannabis sativa. Unlike the more commonly recognized constituent, (−)-Δ²-tetrahydrocannabinol, CBD does not exhibit psychotropic effects as it is not an agonist at cannabinoid 1 receptors (Pertwee, 2008). In fact, CBD is very well tolerated in humans (Cunha et al., 1980). CBD has a plethora of actions, including anti-convulsive, anxiolytic, anti-relapse and neuroprotective properties (Hampson et al., 1998; Mechoulam et al., 2002; Ren et al., 2009), which make it an ideal candidate for treating multiple pathologies associated with AUDs. CBD was initially shown to be neuroprotective in an in vitro model of excitotoxicity by scavenging reactive oxygen species (Hampson et al., 1998). Indeed, comparison of CBD with well-known antioxidants including BHT and α-tocopherol, showed that CBD has a higher antioxidant capacity (Hampson et al., 1998). Extending these findings, another study demonstrated that CBD was neuroprotective in the modified Majchrowicz binge model of alcohol-induced neurodegeneration, presumably through its antioxidant activity (Hamelink et al., 2005).

Although CBD is efficacious in preclinical models and is safe for human use (Cunha et al., 1980), its clinical use has been minimal because of poor oral bioavailability and low aqueous solubility. Estimated oral bioavailability of CBD is roughly 6% (Agurell et al., 1981; Ohlsson et al., 1986); therefore, it is difficult and expensive to achieve suitable plasma levels for clinical efficacy. These drug delivery obstacles may be circumvented by alternative delivery routes, such as transdermal delivery (Paudel et al., 2010). Additionally, transdermal delivery is advantageous because it promotes patient compliance, as this route of administration is non-invasive and pain free compared to injectable formulations, which is especially important in the alcohol dependent population (Swift et al., 2011). Therefore, the current study investigated the utility of CBD transdermal systems for preventing alcohol-induced neurodegeneration using a well-established model of and AUD, the modified Majchrowicz binge model.

2. Materials and methods

2.1. Housing and animals

Adult male Sprague Dawley rats weighing approximately 275–300 g on arrival (n = 148, Charles River, Raleigh, NC) were used in these studies. All treatment protocols followed the Guide for the Care and Use of Laboratory Animals (NRC, 1996) and were approved by the University of Kentucky Institutional Animal Care and Use Committee. Rats were singly housed in Plexiglas cages in an AAALAC approved University of Kentucky vivarium on a 12 h light/dark cycle with access to rat chow and water ad libitum unless noted. During acclimation, rats were handled daily for at least 3 days to familiarize rats to experimenters.

2.2. Ethanol treatment

Rats were exposed to ethanol following the modified Majchrowicz binge model (Majchrowicz, 1975) as reported previously (Morris et al., 2010). This model maintains intoxicating blood ethanol concentrations (BECs) typical of AUDs (Urso et al., 1981), with minimal mortality and a well-defined pattern of neurodegeneration (Collins et al., 1996; Kelso et al., 2011). Rat chow was removed from home cages and rats were administered with either ethanol (25% w/v) in nutritionally complete Vanilline Ensure Plus® (Abbott Laboratories, Columbus OH) or an isocaloric diet consisting of dextrose, water and Vanilline Ensure Plus® every 8 h for 4 days by intragastric gavage. Ethanol rats initially received a 5 g/kg priming dose, with subsequent doses based off the following intoxication scale: 0, Normal (5 g/kg); 1, slightly ataxic and hypoactive (4 g/kg); 2, ataxic with elevated abdomen and intact righting reflex (3 g/kg); 3, delayed righting reflex and lack of abdominal elevation (2 g/kg); 4, lack of righting reflex with intact eye blink reflex (1 g/kg); 5, unresponsive including loss of eye blink reflex (0 g/kg). BECs were measured in plasma from tail blood collected 90 min after the 7th dose of ethanol (day 3). Approximately 150 μL of blood was collected into microcentrifuge tubes containing heparin (5 μL; AAT Pharmaceuticals, Schaumberg, IL), centrifuged at 1800 × g for 5 min, and stored at − 20 °C. BECs were determined in triplicate using a AM1 alcohol analyzer (Analog, Lunenburg, MA) calibrated to a 300 mg/dL external standard.

2.3. Cannabidiol regimen

CBD was synthesized by AllTranz Inc. and formulated for either intraperitoneal (IP) injection or transdermal gel application. CBD (6 mg/mL) and vehicle solutions for IP injections were prepared daily prior to the morning dose. IP solutions were comprised of 76% sterile saline, 21% cremophor and 3% absolute ethanol. The 1%, 2.5%, and 5% (w/w) CBD gels and vehicle gels were prepared and loaded into syringes for gel application. The active and vehicle gels prepared by AllTranz Inc. were composed of ethanol, propylene glycol, sterile water, Transcutol®, preservatives and a crosslinked polyacrylate polymer adjusted to the appropriate pH with triethanolamine to provide suitable rheological properties and pH dependent CBD stability. The optimized formulation described in Experiment 2 utilized only a 2.5% (w/w) CBD gel that contained decreased levels of ethanol and an increase in water content. Rats receiving gels had hair removed on their dorsal side using clippers prior to binge treatment and 24 h before the first gel application. Rats received CBD or vehicle starting after the third dose of ethanol by either daily gel application (11:00 am) or IP injection (20 mg/kg) twice daily (11:00 am and 11:00 pm; see Fig. 1A). This IP dose was chosen based off a previous study demonstrating CBD mediated neuroprotection using a similar binger model (Hamelink et al., 2005). Gels (750 μL) were applied to a 35 cm² area and rubbed into the skin for 30 s with a finger covered by a nitrile glove.

2.4. Cannabidiol quantification

To determine plasma CBD concentrations, additional tail blood was collected on day 3 and trunk blood was collected during euthanasia. Approximately 250 μL of blood was collected and placed into silanized microcentrifuge tubes containing heparin, centrifuged at 10,000 × g for 3 min and plasma was stored at − 70 °C until quantification by LC–MS. CBD was extracted according to previously described methods (Paudel et al., 2010). Briefly, CBD was extracted from 50 μL of plasma using 500 μL of acetonitrile (ACN)/ethanol acetate (1:1, v/v). Samples were vortexed for 1 min, centrifuged for 20 min at 10,000 × g and supernatants were placed into siliconized test-tubes and evaporated under nitrogen at 37 °C. Samples were reconstituted with 100 μL of ACN, vortexed for 1 min and sonicated for 5 min before transfer to HPLC vials with silanized low volume HPLC inserts and placed in a Waters Alliance® 2695 HPLC system. CBD was resolved using a Waters Symmetry® C₁₈ reversed phase column (5 μm, 2.1 × 150 mm; Milford, MA) fitted with a Sentry Symmetry® C₁₈ (3.5 μm, 2.1 × 10 mm) guard column and a mobile phase consisting of ammonium acetate (2 mM); ACN (30:70 or 35:65 v/v) at a flow rate of 0.25 mL/min. Electrospray
effect are observed following either FJB or silver staining (Cippitelli et al., 2012), suggesting that FJB is an appropriate alternative to silver stain. FJB staining was performed according to the manufacturer’s instructions (Millipore, Billerica, MA) as previously described (Obernier et al., 2002; Leasure and Nixon, 2010). A 1:12 series for each animal was washed (3 × 5 min in TBS) then mounted on Super Frost Plus® slides (Fisher Scientific, Pittsburgh, PA) and allowed to air dry overnight.

Sections were then rehydrated (5 min, 1% sodium hydroxide in 80% ethanol; 2 min, 70% ethanol; 2 min, ddH₂O), incubated in 0.06% potassium permanganate for 10 min while gently shaking, rinsed in ddH₂O for 2 min and stained with 0.001% (w/v) FJB in 0.1% (v/v) acetic acid for 20 min while gently shaking in the dark. Sections were further rinsed (3 × 1 min) with ddH₂O in the dark, dried on a covered slide warmer and cover-slipped in Cytoseal® (Richard Allen Scientific, Kalama, MI). FJB positive (+) cells were quantified at 200× or 400× magnification using an Olympus BX-51 microscope equipped for epifluorescence with a 488λ cube for blue excitation. The entorhinal cortex was defined using a rat brain atlas (Paxinos and Watson, compact 6th edition, 2009) and FJB + cells were counted in the entorhinal cortex from −3.60 mm through −6.12 mm from bregma and averaged as the number of FJB+ cells/section. Although, neurodegeneration can be detected throughout the cortico–limbic pathway, only the entorhinal cortex was quantified as a screen for CBD effects because this brain region has the most reproducible injury severity. Stereology was not used because the entorhinal cortex does not have readily identifiable boundaries necessary for implementing stereological procedures and tissue thickness is difficult to accurately measure with the low background characteristic of FJB staining. Strict criteria were used to identify FJB + cells: cells were included if they were in cortical layers II or III, displayed a pyramidal cell body characteristic of neurons, and/or had observable proximal dendrites. FJB + cells were rarely observed in control rats (<1 cell/section) regardless of CBD treatment and were not significantly different, therefore were collapsed into a single control group for each study.

2.6. Statistical analysis

Statistics were performed using GraphPad Prism (GraphPad version 4.03, La Jolla, CA, USA). Average intoxication behavior was analyzed by Kruskal–Wallis tests followed by Dunn’s post-hoc tests when appropriate. Average daily dose, BECs, and CBD plasma concentrations were analyzed by ANOVAs followed by Bonferroni post-hoc tests when appropriate. FJB data was analyzed using ANOVAs followed by planned post-hoc t-tests. Significant variability in FJB cell counts was expected based on previous experience with the binge model; therefore, experiments were designed a priori with the intention of collapsing ethanol and ethanol + vehicle rats in order to reduce the number of animals used while maintaining power. Additionally, the experiments were designed a priori to collapse control groups as FJB is rarely observed (<1 cell/section) regardless of CBD treatment and were not significantly different, therefore were collapsed into a single control group for each study.

Values are presented as mean ± standard error of the mean and analyses were considered significant at p < 0.05.

3. Results

3.1. Experiment 1: Determination of a neuroprotective target CBD plasma concentration following of CBD transdermal delivery

Experiment 1 tested the neuroprotective effects of 1.0% (n = 5), 2.5% (n = 4) and 5.0% (n = 6) CBD gels. First, in order to rule out potentially confounding effects of CBD or vehicle treatment on ethanol pharmacokinetics and intoxication; intoxication behavior, ethanol dose and BECs were compared across treatment groups. Rats treated with ethanol only (n = 9) and ethanol plus vehicle gel (n = 6) were indistinguishable across all measured variables, therefore these groups were collapsed. Regardless of treatment, all rats displayed similar

Please cite this article as: Liput DJ, et al. Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder, Pharmacol Biochem Behav (2013), http://dx.doi.org/10.1016/j.pbb.2013.08.013
intoxication behavior across the 4 days of binge treatment (Fig. 2A). The grand mean intoxication behavior was 2.5 ± 0.1 out of 5, which is indicative of rats being intoxicated to the level where they displayed a delayed righting reflex and ataxia. Analysis of mean intoxication behavior (Fig. 2A inset) revealed a main effect of treatment \( [H_{(3)} = 8.258; p < 0.05] \) and post-hoc tests indicated a significant difference between the ethanol/ethanol and ethanol + 1.0% CBD groups \( (p < 0.05) \). Although a significant difference in intoxication was observed between these two groups, the effect was not large enough to result in different amounts of ethanol administered. The grand mean ethanol dose for rats in this experiment was 8.2 ± 0.2 g/kg/day, which was not different between groups (Fig. 2B). Accordingly, the grand mean peak BEC was 436.9 ± 11.1 mg/dL. Although one-way ANOVA revealed a significant effect of treatment \( [F_{(3,29)} = 3.085; p = 0.045] \), post-hoc analysis failed to reveal a significant difference between groups (Fig. 2C). These data indicate that transdermal vehicle or transdermal CBD did not alter the intoxicating effects or pharmacokinetics of ethanol. Additionally, these binge data are similar to previous reports using the modified Majchrowicz binge model (Morris et al., 2010).

Substantial FJB+ staining was observed in the entorhinal cortex following 4 days of binge ethanol treatment (Fig. 3). These cells were typically found in cortical layers II and III adjacent to the rhinal fissure and extending ventrally. FJB+ cells were rarely observed in control rats and control groups did not differ significantly, therefore, all controls were collapsed (n = 22). Ethanol only and ethanol + vehicle gel rats displayed statistically similar FJB+ cell counts, therefore these groups were collapsed prior to analysis. One-way ANOVA revealed a main effect of treatment \( [F_{(4,47)} = 13.71, p < 0.0001] \). Post-hoc tests indicated that rats treated with 1.0% or 2.5% CBD gels had similar FJB+ cell counts as ethanol/ethanol + VEH gel rats. However, rats treated with 5.0% CBD gels had a 48.8% reduction in the number of FJB+ cells, which trended to statistical significance \( (p = 0.069) \).

CBDD plasma concentrations were analyzed at the beginning of day 3 and at euthanasia (Fig. 1A). Control rats treated with 2.5% CBD gel were not included in this experiment therefore a two-way ANOVA was not performed. However, a one-way ANOVA of ethanol groups revealed a main effect of CBD gel percentage \( (F_{(4,12)} = 4.492, p < 0.05) \). Post-hoc analysis showed that 5.0% CBD gels resulted in significantly higher CBD plasma concentrations compared to the 1.0% CBD gel group \( (p < 0.05) \). However, at euthanasia, CBD plasma concentrations were similar between ethanol groups \( (F_{(2,13)} = 0.29; p > 0.05) \).

3.2. Experiment 2: Neuroprotective effects of an optimized CBD transdermal delivery system and IP CBD delivery

Ethanol intoxication measures in this experiment were similar to Experiment 1 and the intoxicating effects of ethanol were similar between ethanol only (n = 13), vehicle IP (n = 12), CBD IP (n = 15), vehicle gel (n = 7) and CBD gel (n = 9) groups across the 4 days of binge treatment (Fig. 5A). The grand mean intoxication score was 2.2 ± 0.1 (Fig. 5A inset); thus rats in this experiment were intoxicated to the level of delayed righting reflexes and ataxia. Additionally, each treatment group in this study received similar doses of ethanol, which on average were 8.4 ± 0.2 g/kg/day (Fig. 5B). The grand mean peak BEC for this experiment was 380.4 ± 7.8 mg/dL, which did not differ between groups (Fig. 5C), confirming that the drug treatments had no effect on the intoxicating effects or pharmacokinetics of ethanol.

Four days of binge ethanol exposure resulted in neurodegeneration as indicated by the presence of FJB+ cells along the entorhinal cortex. The severity of ethanol-induced damage in the entorhinal cortex was similar across Experiment 1 (Fig. 3) and Experiment 2 (Fig. 6). Similar to Experiment 1, controls (n = 40) were statistically similar and therefore collapsed across drug treatment. In contrast to the analysis conducted in Experiment 1, ethanol only and ethanol + vehicle groups were not collapsed because the vehicles in this study were delivered by different routes of administration. One-way ANOVA revealed a main effect of treatment \( [F_{(5,84)} = 10.63, p < 0.0001] \). Post-hoc analysis indicated that administration of CBD by IP administration significantly reduced FJB+ cells in the entorhinal cortex by 50.6% compared to the ethanol only group \( (p < 0.05) \). Similarly, transdermal administration of CBD significantly reduced FJB+ cells in the entorhinal cortex by 56.1% compared to the ethanol only group \( (p < 0.05) \). Although IP and transdermal CBD administration reduced FJB+ cells by 49.0% and 51.0% compared to their respective vehicle controls, this effect did not reach statistical significance \( (p > 0.05) \).

The mean plasma concentration from the 5% CBD gel group in Experiment 1 (Fig. 4) was used as a target concentration for Experiment 2 as

Fig. 2. Binge treatment data for Experiment 1. Rats were treated according to the modified Majchrowicz binge paradigm and administered with nothing, vehicle, 1%, 2.5% or 5.0% CBD gel formulations. Ethanol only and ethanol + vehicle groups were statistically similar and therefore collapsed (black bars). Behavioral intoxication scores were similar across groups regardless of treatment (A, left axis), therefore each group received similar doses of alcohol (A, right axis). Although mean intoxication score for the 1.0% CBD gel group was significantly lower compared to the vehicle group (A inset), the average daily doses and blood ethanol concentrations did not differ between treatment groups (B–C). Collectively, the binge treatment data shows that CBD gel or vehicle gel treatment did not alter the pharmacokinetics or intoxicating effects of ethanol, \( * p < 0.05 \). Tx = treatment.

Please cite this article as: Liput DJ, et al, Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder, Pharmacol Biochem Behav (2013), http://dx.doi.org/10.1016/j.pbb.2013.08.013
this group displayed promising neuroprotective effects. Therefore, a plasma concentration of ~100 ng/mL was attainable on average (Fig. 7A). Two-way ANOVA revealed main effects of diet \( [F_{(1,25)} = 7.480; \ p < 0.05] \) and time-point \( [F_{(1,25)} = 14.75; \ p < 0.001] \), with a significant interaction \( [F_{(1,25)} = 7.398; \ p < 0.05] \). Post-hoc analysis revealed that CBD plasma levels were significantly lower in binge ethanol treated rats at the day 3 time-point compared to controls \( (p < 0.01) \). Additionally, control CBD plasma levels during euthanasia were significantly lower than at day 3 \( (p < 0.001) \). CBD plasma levels following IP administration (40.0 mg/kg/day) were substantially higher than concentrations achieved following transdermal application (Fig. 7B) and were indistinguishable between control and ethanol treated rats.

4. Discussion

The current study examined the neuroprotective effects of transdermal CBD systems in an accepted model of an AUD that produces substantial neurodegeneration in the cortico–limbic pathway. The first experiment was a pilot study to determine CBD plasma concentrations necessary to observe neuroprotection following transdermal CBD treatment. The 5% gel formulation in this experiment produced promising neuroprotective effects, a 48.8% decrease, while the 1.0% and 2.5% gels were ineffective (Fig. 3). The mean day 3 CBD plasma concentration for the 5% CBD gel group was ~100 ng/mL and was used as a target concentration because neuroprotection outcomes were promising for this group (Fig. 4). In Experiment 2, an optimized formulation was developed by AllTranz Inc. to efficiently deliver CBD at the target plasma concentration while using less CBD (Fig. 7). Importantly, the neuroprotective effects of transdermal delivery of CBD were comparable to the magnitude of neuroprotection observed following IP injection (Fig. 6). Although the degree of neuroprotection appeared to be modest, a 50–60% reduction in FJB+ cells in the entorhinal cortex is similar to previous studies testing neuroprotective agents using the same 4-day binge model (Hamelink et al., 2005; Crews et al., 2006; Cippitelli et al., 2010, 2012). Therefore, these results justify further preclinical development of transdermal CBD for the treatment of alcohol-induced neurodegeneration. Furthermore, preclinical development of neuroprotective agents for the treatment of AUDs is warranted because alcohol-induced brain damage is hypothesized to be critical in promoting impairments in executive self-regulatory behavior, thus contributing to the downward spiral to addiction (Koob and Le Moal, 1997; Crews, 1999).

Interestingly, this study showed that transdermal and IP delivery of CBD produced similar magnitudes of neuroprotection although IP administration resulted in substantially higher CBD plasma levels. Although a full dose–response experiment was not conducted, the current data could suggest that the maximum effective concentration \( (EC_{\text{max}}) \) of CBD was achieved following both routes of administration. However, an earlier study by Hamelink et al. failed to...
Therefore, an alternative interpretation to explain the similar magnitudes of neuroprotection following transdermal and IP administration of CBD could be that transdermal administration at these doses optimizes brain distribution of CBD.

Importantly, we observed a positive relationship between CBD gel percentage and day 3 CBD plasma concentrations in ethanol treated rats, while CBD plasma concentrations were similar across the 1.0%, 2.5% and 5.0% CBD groups during euthanasia (Fig. 4). Although CBD plasma levels were similar at euthanasia, only 5.0% CBD resulted in promising neuroprotective effects (Fig. 3). These observations highlight the importance of administering CBD at therapeutic levels early during binge ethanol treatment. CBD treatment was initiated following the third dose of ethanol (Fig. 1A), similar to other studies demonstrating neuroprotection following antioxidant treatment (Hamelink et al., 2005; Crews et al., 2006). Neuroprotective agents are likely to be more efficacious when administered at these early time-points because cellular stress and neurodegeneration can be detected following as few as 1 or 2 days of binge ethanol treatment (Crews et al., 2000; Hayes et al., 2009). In contrast to these reports, our studies demonstrated that CBD is neuroprotective at therapeutic levels administered either as a pretreatment study would mimic. However, a prophylactic strategy should not be dismissed and may enhance the value of transdermal CBD delivery in managing relapse events. For example, an individual could apply a CBD patch if a relapse event occurred and not prophylactically as a pretreatment in addition to treatment during binge exposure; however this strategy was not implemented in order to mimic a feasible human application for transdermal CBD. For example, an individual could apply a CBD patch if a relapse event occurred and not prophylactically as a pretreatment study would mimic. However, a prophylactic strategy should not be dismissed and may enhance the value of transdermal CBD for the treatment of a variety of other pathologies associated with AUDs in addition to alcohol-induced neurodegeneration. Alcoholism is a cyclical disease consisting of periods of binge intake, acute physical withdrawal, protracted withdrawal and ultimately recurrent relapse, which all may be treated by extended release formulations of CBD (Mechoulam et al., 2002; Ren et al., 2009; Scuderi et al., 2009). For example CBD has anti-convulsant effects (acute withdrawal), antioxidant properties, it is possible that CBD attenuates oxidative stress (Nixon et al., 2009). Impairment in mitochondrial function is likely a causal factor contributing to alcohol-induced neurodegeneration as these impairments result the production of oxidative stress (Nixon et al., 2009). As CBD is thought to be neuroprotective partially through antioxidant properties, it is possible that CBD attenuates oxidative stress caused by impairments in the mitochondrial electron transport chain. Collectively, these results suggest that neuroprotective agents, including transdermal CBD, need to be administered at therapeutic levels before ethanol-induced neurotoxic events are irreversible.

Enhanced neuroprotection might be observed by administering CBD as a pretreatment in addition to treatment during binge exposure; however this strategy was not implemented in order to mimic a feasible human application for transdermal CBD. For example, an individual could apply a CBD patch if a relapse event occurred and not prophylactically as a pretreatment study would mimic. However, a prophylactic strategy should not be dismissed and may enhance the value of transdermal CBD for the treatment of a variety of other pathologies associated with AUDs in addition to alcohol-induced neurodegeneration.

As these impairments result the production of oxidative stress (Nixon et al., 2009). As CBD is thought to be neuroprotective partially through antioxidant properties, it is possible that CBD attenuates oxidative stress caused by impairments in the mitochondrial electron transport chain. Collectively, these results suggest that neuroprotective agents, including transdermal CBD, need to be administered at therapeutic levels before ethanol-induced neurotoxic events are irreversible.
developmental hurdles that need to be overcome in order to translate the results of the current study into a feasible treatment for AUDs. For example, plasma concentrations achieved by the first generation gel formulation in Experiment 1 were consistently higher in ethanol treated rats (Fig. 4), while the second generation gel formulation resulted in lower CBD plasma concentrations in ethanol treated rats compared to controls at day 2 (Fig. 7). Although the reason for the discrepancy between Experiment 1 and Experiment 2 is unknown, this observation may be related to intrinsic differences in the transdermal flux of CBD between the two formulations. It is also possible that the high BECs achieved during binge ethanol treatment may interfere with the pharmacokinetics of transdermal CBD. For example, studies have shown that forced ethanol consumption in rodents, producing BECs greater than 100 mg/dL, can result in moisture loss in the stratum corneum (Brand and Jendrzejewski, 2008). Dehydration of the stratum corneum could theoretically affect CBD transdermal flux. Furthermore, it is well-known that ethanol interferes with the metabolism of drugs (Weathermon and Crabb, 1999). For example, acute ethanol exposure commonly inhibits hepatic metabolism, while chronic ethanol exposure enhances drug metabolism and clearance (Lieber, 1997). Although it is currently unknown whether altered transdermal flux or metabolism of CBD occurs following binge ethanol treatment, and the current studies were not designed to examine full pharmacokinetic profiles following transdermal delivery of CBD, these considerations are important for future drug development efforts. Even though binge ethanol treatment resulted in alterations in CBD plasma concentrations following transdermal application, one could still argue that transdermal delivery in an alcoholic population may be advantageous if future studies demonstrate efficacy for these other pathologies associated with AUDs. Furthermore, transdermal delivery of other medications, such as naltrexone and acamprosate, could enhance the utility of pharmacotherapy based treatments for alcohol dependence in general. Transdermal delivery is a controllable extended release formulation (Paudel et al., 2010), therefore improves patient compliance because medications can be administered less frequently. Additionally, transdermal products are non-invasive which promotes patient friendly usage, in contrast to injectable formulations. These are important considerations for treating AUDs as compliance has been low for currently approved medications (Swift et al., 2011).

Although the results of the current study are promising, there are developmental hurdles that need to be overcome in order to translate these findings into a feasible treatment for AUDs. For example, plasma concentrations achieved by the first generation gel formulation in Experiment 1 were consistently higher in ethanol treated rats (Fig. 4), while the second generation gel formulation resulted in lower CBD plasma concentrations in ethanol treated rats compared to controls at day 2 (Fig. 7). Although the reason for the discrepancy between Experiment 1 and Experiment 2 is unknown, this observation may be related to intrinsic differences in the transdermal flux of CBD between the two formulations. It is also possible that the high BECs achieved during binge ethanol treatment may interfere with the pharmacokinetics of transdermal CBD. For example, studies have shown that forced ethanol consumption in rodents, producing BECs greater than 100 mg/dL, can result in moisture loss in the stratum corneum (Brand and Jendrzejewski, 2008). Dehydration of the stratum corneum could theoretically affect CBD transdermal flux. Furthermore, it is well-known that ethanol interferes with the metabolism of drugs (Weathermon and Crabb, 1999). For example, acute ethanol exposure commonly inhibits hepatic metabolism, while chronic ethanol exposure enhances drug metabolism and clearance (Lieber, 1997). Although it is currently unknown whether altered transdermal flux or metabolism of CBD occurs following binge ethanol treatment, and the current studies were not designed to examine full pharmacokinetic profiles following transdermal delivery of CBD, these considerations are important for future drug development efforts. Even though binge ethanol treatment resulted in alterations in CBD plasma concentrations following transdermal application, one could still argue that transdermal delivery in an alcoholic population may be advantageous compared to oral delivery. Chronic alcohol dependence has dual effects on hepatic metabolism: during ethanol exposure ethanol inhibits hepatic enzyme activity, while enzyme activity can be induced in the absence of ethanol. These contrasting effects on hepatic metabolism can lead to significant variation in systemic blood levels after oral dosing of drugs subjected to high first pass metabolism, such as CBD. Transdermal CBD gels would bypass the first pass effect and thus would be less influenced by the effects of ethanol on hepatic metabolism, leading to more stable systemic blood levels. Even in light of these technological issues, neuroprotection was observed following transdermal CBD delivery. Therefore, future drug development studies are warranted and

Please cite this article as: Liput DJ, et al, Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder, Pharmacol Biochem Behav (2013), http://dx.doi.org/10.1016/j.pbb.2013.08.013
should be focused on further understanding and optimizing transfer- 
slow CBD systems in intoxicated rodents.

Conflict of interest

Aurda Stinchcomb and Dana Hammell are significant shareholders in 
AIflTranz, a transdermal specialty pharmaceutical company devel-
opning cannabinoid-based products.

Acknowledgments

We extend our gratitude to Stan Banks, Ph.D. for his assistance in 
the preparation of this report. This work was supported by funding from the 
National Institute of Alcohol Abuse and Alcoholism grants AA016959 
(KN), AA016499 (KN), and AA019853 (DJL), the National Institute on 
Drug Abuse grants DA016176 (DJL) and R43DA32161 (ALS), and the 
Kentucky Science and Technology Corporation grant KSTC-184-512- 
07-629 (ALS). Sponsors had no contribution to the execution, interpre-
tation or preparation of the current report.

References

1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administra-

Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al. Molecular tar-
gets for cannabinoid and its synthetic analogues: effect on vanilloid VR1 receptors 
and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 
2001;134:S45–52.

Brand RM, Jendrezejewski JL. Chronic ethanol ingestion alters xenobiotic absorption 
through the skin: potential role of oxidative stress. Food Chem Toxicol 2008;46: 
1940–8.

effect of cannabinol in an in vivo model of newborn hypoxic-ischemic brain 
damage in mice is mediated by CB(2) and adenosine receptors. Br J Pharmacol 
2010;159:37–44.

effect: cannabinol, cannabidiol, cannabigerol following oral administration in 

Kent OS, Bardhan KD, Lovat D, Greenhalgh DG. Cannabidiol and cannabigerol after 
oral administration: effect on pain thresholds, nausea and vomiting. Br J Phar-

Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997;278: 
1044–5.

Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997;278: 
1044–5.

Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997;278: 
1044–5.

Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997;278: 
1044–5.

Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997;278: 
1044–5.

Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997;278: 
1044–5.

Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997;278: 
1044–5.

Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997;278: 
1044–5.

Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997;278: 
1044–5.